Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
about
Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report.Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment<sup/>.Managing Drug Interactions in Cancer Therapy: A Guide for the Advanced Practitioner
P2860
Q34494657-D91589D5-849E-4B6B-99FC-87A597D77E2AQ38712723-30D4F651-5BD8-4E39-A5CD-05B02E23682BQ38928302-36610462-2CF4-4643-9EE5-2DC183FF5871Q39002032-682411C4-CBEE-473A-8541-6443594EE412Q39031326-778A8C67-635C-49BC-BF77-FC3BF9F70DC0Q39639310-B4ED2AA5-9A89-407C-A1F7-2A64FCB2E734Q39735712-7369F9C1-4FEA-495F-AD05-5C84592F23C3Q40122845-4112748C-46D6-4AEF-A736-261B60FCD007Q42368314-86F0EE3D-FFDE-436B-A837-D0404C8CE277Q47424342-2559460B-CC79-4EE5-AFB1-9BCDD04F7051Q50121608-D20994F7-1BDD-40EF-A338-E4552BBF510CQ53963822-E3B5A2A1-105D-4071-A359-0DD5DE417427Q54178349-706C5ADB-AD0E-4512-8BCF-C7C2071C5AB8Q54987383-81FF10F3-9504-4BD6-AA92-06E44CD3D75AQ55021587-985B1E4E-988C-4EC5-B8B8-6765725BB1B0Q57498748-8A63F436-486A-4FF3-B817-266A995A41CC
P2860
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
@ast
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
@en
type
label
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
@ast
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
@en
prefLabel
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
@ast
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
@en
P2093
P2860
P356
P1476
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
@en
P2093
Donna Skee
Erik Mannaert
Jan Snoeys
Jan de Jong
Joe Murphy
Johan Smit
Juhui James Jiao
Juthamas Sukbuntherng
Peter Hellemans
Ronald de Vries
P2860
P304
P356
10.1002/PRP2.156
P577
2015-06-24T00:00:00Z